Mariam Alexander

Thoracic Med Onc @MUSChealth @muschollings Charleston, South Carolina. Former Heme/Onc fellow @MontefioreNYC @EinsteinMed

[Patrick Forde @FordePatrick]

Should bring academic oncologists down to earth ~50% of pts 65yo+ with advanced nsclc in US never receive any systemic anti cancer treatment #lcsm https://t.co/cnirAamhtP

[Stephen V Liu, MD @StephenVLiu]

Lots of discussion about the future landscape for SCLC at the IS Focus Meeting on Lung Cancer with great talks by Drs. @alissajcooper @HosseinBorghaei @MariamAlex26 @dominicandoc2 - where will ADCs end up making the biggest contribution?

[Mariam Alexander @MariamAlex26]

@BalazsHalmosMD @HosseinBorghaei @CharuAggarwalMD @StephenVLiu @Shuai_WangOnc @HyeinJeon_MD So nice to see the Monte crew!

[Balazs Halmos @BalazsHalmosMD]

Congrats on a first US Focus Meeting on Lung Cancer where @CharuAggarwalMD and @StephenVLiu got just the right pieces together to build a great event- including a Monte mini-reunion in Honky-Tonk town
@Shuai_WangOnc @HyeinJeon_MD

[Abi Siva MD @AbiSivaMD]

Honored to share this @ASCO Connect piece on my career journey 🙏 Grateful to @CliffordHudis for highlighting it 🙌 Wonderful 10+ years of growth, networking, and friendships ✨ More to come. "Where You Start Does Not Define Where You Can Go”: Dr. Abirami Sivapiragasam’s Journey and Reflections for Early-Career Oncologists | ASCO Connection https://t.co/yapoNZrlUj

[Mariam Alexander @MariamAlex26]

@AbiSivaMD @Rndubois @muschollings Thanks @AbiSivaMD !! You’re the best

[Stephen V Liu, MD @StephenVLiu]

FDA approves subcutaneous amivantamab - finally! This is a no-brainer switch in my opinion. Faster, decrease risk of infusion reaction, less risk of VTE. Even possibility of greater efficacy versus IV (needs confirmation). Will switch as soon as we can.

https://t.co/NMbP93ZzgE

[IASLC @IASLC]

.@anguspratt was a giant in the lung cancer community.

An advocate, friend, and warm, unforgettable presence.

His legacy lives on in the research and advocacy he championed.

We feel the weight of his loss, and we’ll continue the work that meant so much to him.

[Jarushka Naidoo @DrJNaidoo]

#DCLung25
Hard-hitting talk on biomarker testing in NSCLC by @christine_lovly, where she highlights:

- expanding list of targeted therapy
- cannot prescribe, if test is not done
- interpreting lung cancer genomic results has become an ‘in the weeds’ skill

Wow @IASLC #LCSM

[Stephen V Liu, MD @StephenVLiu]

Quick pre #DCLung25 visit to the National Portrait Gallery @smithsoniannpg - my favorite museum in DC - with some of the faculty!

[Stephen V Liu, MD @StephenVLiu]

Wow. Dr. @DrJNaidoo gives the #DCLung audience a true master class on immune related toxicities, debunking myths & providing pearls on long-term management. Steroids are not always the preferred initial treatment. Rechallenge possible. Specific irAEs have different prognosis.

[Jarushka Naidoo @DrJNaidoo]

#DCLung25
My fellow 🇪🇺 speaker at DCLung @Alfdoc2 comprehensively reviews bispecifics, & where they are going in NSCLC. Applications are broad, to:

- IO-responsive tumors (eg Ivonescimab)
- Oncogene+ tumors (eg izi-bren, EGFR)
- the future: bicycles & more!

@IASLC @hug_ge #LCSM

[Mariam Alexander @MariamAlex26]

You are our inspiration @BalazsHalmosMD . Also I have not figured out how you manage to be so funny while being educational. It’s an art!

[Balazs Halmos @BalazsHalmosMD]

@HyeinJeon_MD @Joshua_Reuss @StephenVLiu Great to see you, Hyein and also other amazing Monte grad @MariamAlex26 at #DCLung25 today! It is truly just a special thrill to witness our prior mentees succeeding- wonderful to learn about you taking a fantastic start w @StephenVLiu at MedStar Washington Hospital Center!

[Joshua Reuss @Joshua_Reuss]

Dr. @MariamAlex26 with a comprehensive overview of the symphony of emerging ADCs in lung cancer. Lots of emerging data and smattering of approvals, but ideal biomarkers still needed. #DCLung25

[Mariam Alexander @MariamAlex26]

Thank you @StephenVLiu and @Joshua_Reuss for the kind invitation. Awesome conference. Fun, educational and so well organized

[Stephen V Liu, MD @StephenVLiu]

Beautiful tour of antibody drug conjugates from Dr. @MariamAlex26 at #DCLung25 with new approvals of datopotamab deruxtecan in EGFR mutant NSCLC and telisotuzumab vedotin in MET IHC+ NSCLC. Biomarker development critical to optimal use (NMR QCS) and new classes of ADCs coming!

[Stephen V Liu, MD @StephenVLiu]

Beautiful tour of antibody drug conjugates from Dr. @MariamAlex26 at #DCLung25 with new approvals of datopotamab deruxtecan in EGFR mutant NSCLC and telisotuzumab vedotin in MET IHC+ NSCLC. Biomarker development critical to optimal use (NMR QCS) and new classes of ADCs coming!

[Mariam Alexander @MariamAlex26]

@triparnasen Congratulations!!!!

[Stephen V Liu, MD @StephenVLiu]

Don't miss #DCLung25 - a one-day, @IASLC endorsed comprehensive lung cancer conference on Saturday, October 4th in Washington DC.

Joining us will be Dr. Mariam Alexander @MariamAlex26,
who will outline antibody drug conjugates (ADCs) in lung cancer.

https://t.co/OJz1a1l2RD

[IASLC @IASLC]

The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, @StephenVLiu, @MariamAlex26 & Dr. James Chih-Hsin Yang break down the data and explore clinical impact.

🎧 https://t.co/XSv1K3G9yX

[Mariam Alexander @MariamAlex26]

Such a treat to discuss this important approval and learn about the history of Sunvozertinib development and trial design and nuances of dose/toxicities from Dr James Yang. Thanks @StephenVLiu @IASLC #lcsm @EGFRResisters

[Stephen V Liu, MD @StephenVLiu]

Watch for this episode of the @IASLC podcast Lung Cancer Considered next week - I discuss the latest FDA approval for lung cancer: sunvozertinib, for lung cancer with an EGFR exon 20 insertion. Great discussion and background with Drs. James Chih-Hsin Yang and @MariamAlex26!